Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
AOD 9604 promotes cartilage regeneration, making it beneficial for joint health
GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists These agents are commonly used therapies for managing diabetes and obesity, but gastrointestinal adverse effects such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
In this episode, TRC Healthcare Associate Editor and Clinical Pharmacist Vickie Danaher, PharmD discusses how semaglutide became the first FDA-approved oral GLP-1 agonist for obesity
Beyond weight loss, the expanding therapeutic landscape of GLP-1 agonists now includes cardiovascular risk reduction, peripheral artery disease management, and active clinical trials for neurodegenerative disorders and substance use disorderswith over 15 global trials underway for the latter indication alone
